Spruce Biosciences, Inc. has 28 Schedule 13D or 13G filings on record since 2025-08-13. 5 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Orin Hirschman | 9.1% | 250,000 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| BlackRock, Inc. | 6.8% | 187,836 | SCHEDULE 13G, 2026-07-30 | 2026-06-30 |
| Boone Peter David Mr | 6.4% | 68,184 | SCHEDULE 13G, 2025-11-24 | 2025-11-21 |
| Integrated Core Strategies (US) LLC | 5.8% | 160,981 | SCHEDULE 13G/A, 2026-08-04 | 2026-06-30 |
| AWM Investment Company, Inc. | 5.1% | 146,988 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Ikarian Capital, LLC | 4.8% | 121,356 | SCHEDULE 13G/A, 2026-05-07 | 2026-04-30 |
| OrbiMed Advisors LLC | 4.8% | 132,200 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| The Carlyle Group Inc. | 4.7% | 50,893 | SCHEDULE 13D/A, 2026-02-18 | 2026-02-18 |
| Alyeska Investment Group, L.P. | 4.49% | 61,670 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Wellington Management Group LLP | 3.6% | 48,796 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| HealthCap VIII, L.P. | 3.4% | 36,640 | SCHEDULE 13D/A, 2025-10-09 | 2025-10-07 |
| ADAR1 Capital Management, LLC | 2.5% | 67,717 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Kenneth Griffin | 1.9% | 51,919 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Squadron Master Fund LP | 0.9% | 12,200 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| ExodusPoint Capital Management, LP | 0.8% | 22,000 | SCHEDULE 13G, 2026-04-28 | 2026-04-22 |
| Radoff Family Foundation | 0% | 0 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
| Rock Springs Capital Management LP | 0% | 0 | SCHEDULE 13G/A, 2025-08-13 | 2025-07-03 |
Purpose of Transaction (Item 4)
The Carlyle Group Inc.
Item 4 of the Schedule 13D is hereby amended as follows: Bali Muralidhar, who represented Abingworth Bioventures VII LP on the Issuer's board of directors, resigned as a director in October 2025.Item 4 of the SCHEDULE 13D/A filed 2026-02-18
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Radoff Family Foundation | 0% | SCHEDULE 13G/A |
| 2025-08-13 | Rock Springs Capital Management LP | 0% | SCHEDULE 13G/A |
| 2025-10-08 | Ikarian Capital, LLC | 21.6% | SCHEDULE 13G |
| 2025-10-09 | HealthCap VIII, L.P. | 3.4% | SCHEDULE 13D/A |
| 2025-10-15 | Squadron Capital Management LLC | 6.6% | SCHEDULE 13G |
| 2025-10-16 | Citadel Advisors LLC | 9.99% | SCHEDULE 13G |
| 2025-11-07 | Ikarian Capital, LLC | 11.4% | SCHEDULE 13G/A |
| 2025-11-24 | Boone Peter David Mr | 6.4% | SCHEDULE 13G |
| 2026-02-10 | Wellington Management Group LLP | 5.5% | SCHEDULE 13G |
| 2026-02-17 | Citadel Advisors LLC | 6.5% | SCHEDULE 13G/A |
| 2026-02-17 | ADAR1 Capital Management, LLC | 5.4% | SCHEDULE 13G |
| 2026-02-17 | Alyeska Investment Group, L.P. | 5.79% | SCHEDULE 13G |
| 2026-02-17 | Squadron Master Fund LP | 6.5% | SCHEDULE 13G/A |
| 2026-02-18 | The Carlyle Group Inc. | 4.7% | SCHEDULE 13D/A |
| 2026-02-24 | Integrated Core Strategies (US) LLC | 9.6% | SCHEDULE 13G |
| 2026-04-28 | ExodusPoint Capital Management, LP | 0.8% | SCHEDULE 13G |
| 2026-05-07 | Ikarian Capital, LLC | 4.8% | SCHEDULE 13G/A |
| 2026-05-15 | Wellington Management Group LLP | 3.6% | SCHEDULE 13G/A |
| 2026-05-15 | Citadel Advisors LLC | 5.1% | SCHEDULE 13G/A |
| 2026-05-15 | Alyeska Investment Group, L.P. | 4.49% | SCHEDULE 13G/A |
| 2026-05-15 | Squadron Master Fund LP | 0.9% | SCHEDULE 13G/A |
| 2026-07-27 | Orin Hirschman | 9.1% | SCHEDULE 13G |
| 2026-07-30 | BlackRock, Inc. | 6.8% | SCHEDULE 13G |
| 2026-08-04 | Integrated Core Strategies (US) LLC | 5.8% | SCHEDULE 13G/A |
| 2026-08-14 | OrbiMed Advisors LLC | 4.8% | SCHEDULE 13G |
| 2026-08-14 | Kenneth Griffin | 1.9% | SCHEDULE 13G/A |
| 2026-08-14 | ADAR1 Capital Management, LLC | 2.5% | SCHEDULE 13G/A |
| 2026-08-14 | AWM Investment Company, Inc. | 5.1% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Spruce Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.